000168053 001__ 168053
000168053 005__ 20260202145620.0
000168053 0247_ $$2doi$$a10.1016/j.metabol.2013.10.014
000168053 0248_ $$2sideral$$a85224
000168053 037__ $$aART-2014-85224
000168053 041__ $$aeng
000168053 100__ $$aCenarro, A.
000168053 245__ $$aEffect of nicotinic acid/Laropiprant in the Lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype
000168053 260__ $$c2014
000168053 5203_ $$aBackground: Lipoprotein(a) [Lp(a)] is a lipoprotein in which apolipoproteinB-100 is linked to apolipoprotein(a) [apo(a)]. Significant variation in Lp(a) concentration is specific to LPA gene, which codes for apo(a). Nicotinic acid (NA) is used for treatment of dyslipidemias, and the lowering effect of NA on Lp(a) has been previously reported.
Objective: To evaluate the Lp(a) lowering effect of 1 g/20 mg and 2 g/40 mg day of Nicotinic acid/Laropiprant in subjects with different baseline Lp(a) concentrations and depending on the LPA genotype.
Methods: In an open-label, 10-week study, 1 g/20 mg day of NA/Laropiprant for 4 weeks followed by 6 weeks of 2 g/40 mg day conducted at 3 centers in Spain, 82 subjects were enrolled. Patients were studied at baseline and at the end of both treatment periods and were enrolled in three groups: normal Lp(a) (< 50 mg/dL), high Lp(a) (50–120 mg/dL) and very high Lp(a) (> 120 mg/dL). The LPA genetic polymorphism was analyzed by a real-time PCR.
Results: There was a significant difference in LPA genotypes among Lp(a) concentration groups and an inverse and significant correlation between baseline Lp(a) concentration and LPA genotype was found (R = − 0.372, p < 0.001). There were a significant decrease in total cholesterol, triglycerides, LDL cholesterol, apo B and Lp(a), and a significant increase in HDL cholesterol after NA/Laropiprant treatment, without changes in BMI. However, there were no statistical differences in percentage variation of analyzed variables depending on LPA genotype.
Conclusion: LPA genotype is a major determinant of Lp(a) baseline concentration. However, the lipid lowering effect of NA is not related to LPA genotype.
000168053 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000168053 590__ $$a3.894$$b2014
000168053 591__ $$aENDOCRINOLOGY & METABOLISM$$b39 / 128 = 0.305$$c2014$$dQ2$$eT1
000168053 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000168053 700__ $$0(orcid)0000-0002-1309-4363$$aPuzo, J.$$uUniversidad de Zaragoza
000168053 700__ $$aFerrando, J.
000168053 700__ $$0(orcid)0000-0001-6650-8294$$aMateo-Gallego, R.
000168053 700__ $$aBea, A. M.
000168053 700__ $$aCalmarza, P.
000168053 700__ $$0(orcid)0000-0001-9142-0737$$aJarauta, E.$$uUniversidad de Zaragoza
000168053 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, F.$$uUniversidad de Zaragoza
000168053 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000168053 773__ $$g63, 3 (2014), 365-371$$pMetab. clin. exp.$$tMETABOLISM-CLINICAL AND EXPERIMENTAL$$x0026-0495
000168053 8564_ $$s507874$$uhttps://zaguan.unizar.es/record/168053/files/texto_completo.pdf$$yVersión publicada
000168053 8564_ $$s2247684$$uhttps://zaguan.unizar.es/record/168053/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000168053 909CO $$ooai:zaguan.unizar.es:168053$$particulos$$pdriver
000168053 951__ $$a2026-02-02-14:49:02
000168053 980__ $$aARTICLE